Nvidia set to lose $180 billion in market value today as Meta weighs Google chips
TAMPA - TuHURA Biosciences, Inc. (NASDAQ:HURA) announced Monday that its research on the delta opioid receptor (DOR) in cancer immunotherapy will be featured in an oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando from December 6-9, 2025. The $127.6 million market cap biotech company has seen its shares rise nearly 11% over the past week, according to InvestingPro data.
The presentation will highlight the company's finding that DOR is expressed on myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), which are immune cells that contribute to immunosuppression in the tumor microenvironment.
According to the company, this marks the first demonstration that DOR is expressed on these specific cell types, with research suggesting that DOR inhibition could potentially reprogram their immunosuppressive capabilities.
"With our discovery of DOR expression, and that DOR activation is coupled to mechanisms by which both MDSCs and TAMs contribute to the immunosuppressive phenotype of the tumor microenvironment, we believe that the DOR represents a novel shared target for pharmacologic intervention," said Dr. James Bianco, President and CEO of TuHURA Biosciences, in the press release.
The company will present three separate research findings at the conference, including an oral presentation on DOR expression on MDSCs, a poster on DOR's role in TAMs, and a collaborative poster with Moffitt Cancer Center showing DOR expression on MDSCs from patients with myeloid dysplastic syndrome.
TuHURA Biosciences is developing technologies aimed at overcoming resistance to cancer immunotherapy. The company's lead product, IFx-2.0, is currently in Phase 3 trials as an adjunctive therapy to pembrolizumab for Merkel Cell Carcinoma. The company is also advancing TBS-2025, a VISTA inhibiting monoclonal antibody entering Phase 2 development for acute myeloid leukemia.
The information in this article is based on a press release statement from TuHURA Biosciences.
In other recent news, TuHURA Biosciences reported its second-quarter financial results for 2025, revealing a net loss of $0.21 per share. This result was wider than the previous estimate of a $0.14 per share loss made by H.C. Wainwright. Despite the wider loss, H.C. Wainwright has reiterated its Buy rating for TuHURA Biosciences and maintained a price target of $12.00. These developments reflect the firm's continued confidence in the company's potential. This analysis comes in the wake of TuHURA's financial performance update, which is crucial information for investors. The reiteration of the Buy rating suggests that H.C. Wainwright sees long-term value in TuHURA Biosciences. Investors may find this information valuable as they consider their positions in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.